*Pain Medicine 2016; 17: 2036–2046 doi: 10.1093/pm/pnw245*

OPIOIDS, SUBSTANCE ABUSE & ADDICTIONS SECTION

*Original Research Articles*

Durations of Opioid, Nonopioid Drug, and Behavioral Clinical Trials for Chronic Pain: Adequate or Inadequate?

Baraa O. Tayeb, MD,\*,†,‡,¶,kj Ana E. Barreiro, MPH,\*,†,‡,¶ Ylisabyth S. Bradshaw, DO, MS,\* Kenneth K. H. Chui, PhD,k and Daniel B. Carr, AM, MD, DABPM, FFPMANZCA (Hon)\*,†,‡,¶

\*Program on Pain Research, Education and Policy, Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts; †Departments of Anesthesiology;

‡Medicine; ¶Molecular Physiology and Pharmacology,

and; kPublic Health and Community Medicine, Tufts University School of Medicine, Boston, Massachussetts, USA; kjDepartment of Anesthesia, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

Funding sources: This work was supported by internal funding from Tufts’ Department of Public Health and Community Medicine.

Disclosure and conflicts of interest: Dr. Carr’s spouse was Chief Medical Officer of Steward Health Care dur- ing preparation of this manuscript (until July 1, 2016).

Dr. Tayeb and Ms. Barreiro contributed equally to the prep- aration of the manuscript and served asco–first authors.

*Correspondence to:* Daniel B. Carr, MD, Program on Pain Research, Education and Policy, 136 Harrison Avenue, Boston, MA 02111, USA. Tel: 617-636-3895;

Fax: 617-636-4017; E-mail: [daniel.carr@tufts.edu.](mailto:daniel.carr@tufts.edu)

Abstract

Objectives. A recent US federal review and clinical guideline on opioids for chronic pain asserted that the literature contributes no evidence on efficacy because all trials had “inadequate duration.” To ex- plore the evidence, we examined durations of stud- ies on opioid, nonopioid drug, and behavioral therapies for chronic pain.

Methods. We retrieved Cochrane reviews of anti- convulsants, antidepressants, NSAIDs, opioids, or behavioral interventions for chronic pain. We also examined all opioid treatment studies retrieved for the federal evidence report but excluded due to “in- adequate duration.”

Results. Of 378 Cochrane reviews retrieved, 72 eval- uated one of the five therapies. Six of these 72 were excluded because they were proposals without data or investigated acute pain. Fourteen addressed mul- tiple interventions, leaving 52 for analysis. We graphed numbers of trials vs duration for the five treatments reviewed in the Cochrane Library, com- pared with durations of opioid trials dropped from the federal evidence report. Most graphs were over- dispersed Poisson distributions. Nearly all trials had active treatment durations of 12 weeks or less.

Conclusions. No common nonopioid treatment for chronic pain has been studied in aggregate over longer intervals of active treatment than opioids. To dismiss trials as “inadequate” if their observation period is a year or less is inconsistent with current regulatory standards. The literature on major drug and nondrug treatments for chronic pain reveals similarly shaped distributions across modalities. Considering only duration of active treatment in ef- ficacy or effectiveness trials, published evidence is no stronger for any major drug category or behav- ioral therapy than for opioids.

Key Words. Chronic Pain; Anticonvulsants; Antidepressants; NSAIDs; Opioids; Behavioral

Introduction

The use of opioids began in prehistory [[1](#_bookmark5)] and is now standard practice in much of the world for the manage- ment of acute, chronic, and cancer-related pain. Concerns related to long-term effectiveness, safety, and

Downloaded from <http://painmedicine.oxfordjournals.org/>by guest on November 15, 2016

VC 2016 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: [journals.permissions@oup.com](mailto:journals.permissions@oup.com) 2036

abuse liability of prescription opioids have increased in recent decades, particularly in the United States, as both the numbers of prescriptions for and total doses of opioids have increased markedly [[2](#_bookmark6),[3](#_bookmark7)]. Balancing the le- gitimate medical use of opioids for analgesia vs society- wide abuse, misuse, diversion, addiction, and mortality has become a major public health theme [[4](#_bookmark8)].

Downloaded from <http://painmedicine.oxfordjournals.org/>by guest on November 15, 2016

In March 2016, the US Centers for Disease Control and Prevention (CDC) published a guideline for prescribing opioids for chronic pain on the CDC website [[5](#_bookmark9)]. The guideline’s intent is “to improve communication between clinicians and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy.” An important message communicated in the CDC guideline and related press releases is that the body of evidence ad- dressing the effectiveness or efficacy of opioid therapy for outcomes of pain, function, or quality of life was insuf- ficient to contribute any studies for their analyses. In reaching this conclusion, the minimal duration for inclu-

sion of a long-term study was set by the authors as “>1 year,” the same threshold employed by a 2014 evidence

report [[6](#_bookmark10)] that informed the 2016 CDC guideline. The same consultant was the lead methodologist for both the 2014 evidence report and the 2016 CDC guideline. However, earlier systematic reviews of the effectiveness or efficacy of opioids for chronic noncancer pain [[7](#_bookmark11),[8](#_bookmark12)], co-authored by the same consultant and based upon the best available evidence, had identified dozens of clin- ical trials and systematic reviews of this topic. Although their conclusions were guarded due to the poor overall quality of the literature, both earlier reviews concluded that selected, carefully monitored patients might benefit from such therapy. Because the 2016 CDC literature re- view may be viewed as an update of the earlier reviews, it was striking that the 2016 review reached far more negative conclusions about the risk-benefit ratio for long- term opioid therapy than did the 2009 and 2010 reviews.

The 2014 evidence report and the 2016 CDC guideline relied upon the absence of studies of a year or greater duration to advance recommendations reflecting a low perceived benefit-to-risk ratio of opioid use for chronic pain. We wondered whether a more standard approach to study retrieval and inclusion would confirm or refute this perception. Issues related to study inclusion also have implications for switching from or preferring one therapy to another. If the clinical trial literature supporting one or the other therapy had equivalent distributions of duration and their risk-to-benefit assessments were equivalent, the evidence to support recommending such a switch would be very weak. We therefore sought to characterize the clinical trial literature for chronic pain treatment with an opioid, based upon the literature retrieved for the 2014 Agency for Healthcare Research and Quality (AHRQ) review but excluded by the authors of that review because of “inadequate duration.” In addition, we examined studies cited in in the Cochrane Library of Systematic Reviews addressing opioids, antidepressants,

anticonvulsants, NSAIDs, and behavioral treatments. Our objective was to assess whether differences exist be- tween the duration of treatment trials for chronic pain using each of these modalities, if analyzed without apply- ing the one-year minimum threshold for inclusion newly introduced in the 2014 AHRQ and 2016 CDC reports.

Methods

To prepare a profile of the numbers of studies of various treatments for chronic pain vs the duration of active treatment in each study, we examined each of the clin- ical trials tabulated in Appendix D (“Excluded Studies”) of the AHRQ 2014 evidence review [[6](#_bookmark10)]. Data extraction was carried out independently using Microsoft Excel by two authors (AEB, BOT), who cross-checked each other’s extraction. Two other authors (YSB, DBC) con- ferred as needed to confirm and clarify specifics. A focused third check of study duration and number of participants was performed by (BT) after data entry into Excel; any disagreement was resolved by discussion.

The number of days of observation during active treat- ment included only the interval during which participants received the opioid or other treatment and a measure of effectiveness was captured. For example, we did not in- clude open-label, safety extension phases during which no data on effectiveness was gathered. When the dur- ation of monitored active treatment was not reported in days, we applied the conventions that one week equals seven days, one month equals four weeks, and one year equals 12 months. The number of patients was defined as the total number of actual randomized pa- tients for randomized controlled trials (i.e., not the intent-to-treat population) or the number of patients entering the initial observation period for nonrandomized experimental and observation studies.

Data were extracted from tables of included studies within each review. When such data was lacking or un- clear, we retrieved the full text of the original study to verify or complete any missing data. When the above data was not readily available or not clearly defined, we designated the entry as “unclear.”

To explore the distributions of active treatment duration in the published literature on opioid therapy for chronic pain, as assessed in separate systematic reviews pub- lished independently of the 2014 AHRQ evidence review, we searched the Cochrane Library [[9](#_bookmark13)] for all sys- tematic reviews retrieved in response to the single search term “chronic pain.” We also consulted the Cochrane Library for systematic reviews addressing the literature on other major modalities for chronic pain: anticonvulsants, antidepressants, NSAIDs, and nondrug behavioral therapies. We did not assess other broad categories of analgesic therapies other than those fea- tured in the CDC opioid guideline (e.g., we did not as- sess interventional pain management or complementary and alternative practices). When an individual study within a Cochrane review did not meet our overall

inclusion criteria described above, that study was excluded. Most commonly, such excluded studies were acute pain trials of interventions whose acute and chronic effects were pooled within a single Cochrane re- view, e.g., “gabapentin for pain.” We checked for dupli- cate studies presented within the different Cochrane reviews in each intervention category and removed such duplicates.

Statistical analysis was conducted in three stages. First, we derived descriptive statistics for trial length for each intervention. Then, we visualized the distributions as histograms. Finally, to formally compare the differences between the time frames, we conducted a negative bi- nomial regression using the active treatment duration of each trial as the dependent variable and modality as the categorical independent variable. We selected negative binomial regression over Poisson regression due to the data being overdispersed. Results are reported as risk ratios, each indicating the ratio of mean duration of ac- tive treatment in trials of nonopioid therapies compared with the duration of active treatment in opioid trials excluded for “inadequate duration” from the 2014 AHRQ review. Stata 14 (College Station, TX, USA) was used for data visualization and analysis. Statistically sig- nificant differences were based on the threshold of

*P* < 0.05.

Results

The numbers of articles and systematic reviews retrieved, along with numbers of patients enrolled and the ranges of study durations, are presented in [Table 1](#_bookmark0). The greatest number of included studies was in the category of be- havioral interventions, with 269 articles. The next highest number of included articles was 141 for antidepressants and 148 for the long-term opioids, each approximately half the number for behavioral interventions. The fewest number of articles was for NSAIDS, with 102 articles cov- ering over 34,500 patients. The number of patients included in studies for a specific intervention ranged from over 45,000 for the long-term opioids category in the 2014 AHRQ evidence review to as few as approximately

18,000 patients in the Cochrane reviews of opioids and antidepressants. At the middle range of numbers of pa- tients studied, behavioral interventions and NSAIDS each had approximately 28,000 and 34,000 participants, re- spectively. Anticonvulsant studies enrolled nearly 22,000 and antidepressants over 17,000 patients. Additional de- scriptive statistics for each therapeutic modality, including durations of observation (means, standard deviations modes, and medians), are also presented in [Table 1](#_bookmark0).

Of the retrieved trials in the 2014 AHRQ evidence review, 627 presented in Appendix D of that report did not meet that review’s inclusion criteria; of these, 168 were excluded specifically due to their “inadequate dur- ation.” We retrieved and reviewed all seven abstracts and 161 complete publications deemed of “inadequate duration” and then excluded those studies that did not examine opioid effectiveness (e.g., that compared one NSAID with another in patients receiving opioids) or were reviews rather than primary studies. This process resulted in 148 publications enrolling 45,504 patients.

Our search of the Cochrane Library identified 378 re- views, of which 72 met inclusion criteria. Nine of these reviews were excluded for the following reasons: had no included studies (one study); were of a different class of medication (antipsychotic, one study), were an overview of other already-included Cochrane reviews (one study), or were proposals for future reviews (six “protocols”). After correcting for duplications (i.e., when a single re- view presented information on more than one interven- tion), the end result was 52 reviews comprising 871 individual studies (see [Table 2](#_bookmark1)). Details about the 871 in- dividual included studies are presented in a supplemen- tal file.

To explore differences or similarities between the dur- ation profiles of the opioid trial literature retrieved for but excluded from analysis in the 2014 AHRQ report and Cochrane reviews of opioids and other typical pain treatments, we prepared histograms showing the num- ber of retrieved studies of a given duration of active treatment ([Figure 1](#_bookmark2)). To avoid compressing the

Downloaded from <http://painmedicine.oxfordjournals.org/>by guest on November 15, 2016

# Table 1 Articles, systematic reviews, enrolled patients, duration (range in days), and other descriptive statistics for publications cited in 2014 AHRQ review and Cochrane Library, on treatments for chronic pain

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Articles | Reviews | Patients | Duration (range, d) | Mean duration (SD) | Mode | Median |
| Opioids (AHRQ 2014) | 148 | – | 45,504 | 1 to 2,352 | 76 (220) | 7 | 28 |
| Opioids (Cochrane) | 101 | 9 | 17,796 | 1 to 1,344 | 178 (301) | 1 | 52.5 |
| Anticonvulsants | 108 | 13 | 22,064 | 5 to 1,176 | 62 (114) | 56 | 56 |
| Antidepressants | 141 | 13 | 17,872 | 2 to 189 | 58 (37) | 56 | 56 |
| NSAIDS | 102 | 6 | 34,531 | 4 to 364 | 37 (49) | 42 | 28 |
| Behavioral | 269 | 14 | 28,309 | 1 to 756 | 66 (70) | 56 | 56 |
| Total | 869 | 55 | 166,076 | – | – | – | – |

See text for full explanation of retrieval process. Note that several reviews contributed to more than one therapeutic category; removal of multiple citations of the same review (e.g., [Chaparro 2012 [10]](#_bookmark15) cited under opioids as well as anticonvulsants and antidepressants) reduces the actual total of distinct retrieved reviews to 52 instead of 55.

# Table 2 Cochrane systematic reviews of drug and nondrug modalities to treat chronic pain

Modality Included reviews

Opioids Chaparro 2012 [[10](#_bookmark15)], Chaparro 2013 [[11](#_bookmark17)], Gaskell 2014 [[12](#_bookmark20)], Haroutounian 2012 [[13](#_bookmark22)], McNicol 2013

[[14](#_bookmark24)], Noble 2010 [[8](#_bookmark12)], Quigley 2002 [[15](#_bookmark25)], Santos 2015 [[16](#_bookmark27)], Wrzosek 2014 [[17](#_bookmark29)]

Anticonvulsants Aboumarzouk 2012 [[18](#_bookmark31)], Chaparro 2012 [[10](#_bookmark15)], Gurusamy 2016 [[19](#_bookmark33)], Gill 2011 [[20](#_bookmark36)], Hearn 2012 [[21](#_bookmark38)],

Moore 2009 [[22](#_bookmark14)], Moore 2014 [[23](#_bookmark16)], Moore 2015 [[24](#_bookmark18)], Mujakperuo 2010 [[25](#_bookmark19)], U€ c¸eyler 2013 [[26](#_bookmark21)],

Wiffen 2013 [[27](#_bookmark23)], Wiffen 2013 [[28](#_bookmark26)], Wiffen 2014 [[29](#_bookmark28)]

Antidepressants Chaparro 2012 [[10](#_bookmark15)], Cording 2015 [[30](#_bookmark30)], Derry 2015 [[31](#_bookmark32)], Derry 2015 [[32](#_bookmark34)], Gallagher 2015 [[33](#_bookmark35)],

Hauser 2013 [[34](#_bookmark37)], Hearn 2014 [[35](#_bookmark39)], Lunn 2014 [[36](#_bookmark41)], Moore 2015 [[37](#_bookmark43)], Saarto 2007 [[38](#_bookmark45)], Tort 2012

[[39](#_bookmark47)], Urquhart 2008 [[40](#_bookmark49)], Walitt 2015 [[41](#_bookmark50)]

NSAIDs Garner 2005 [[42](#_bookmark53)], Moore 2015 [[43](#_bookmark54)], Mujakperuo 2010 [[25](#_bookmark19)], Roelofs 2008 [[44](#_bookmark55)], Derry 2012 [[45](#_bookmark57)],

Derry 2014 [[46](#_bookmark60)]

Behavioral Anie 2015 [[47](#_bookmark62)], Bernardy 2013 [[48](#_bookmark40)], Boldt 2014 [[49](#_bookmark42)], Eccleston 2014 [[50](#_bookmark44)], Eccleston 2014 [[51](#_bookmark46)],

Fisher 2015 [[52](#_bookmark48)], Henschke 2010 [[53](#_bookmark51)], Kamper 2014 [[54](#_bookmark52)], Karjalainen 1999 [[55](#_bookmark56)], Karjalainen 2003

[[56](#_bookmark58)], Monticone 2015 [[57](#_bookmark59)], Price 2008 [[58](#_bookmark61)], Theadom 2015 [[59](#_bookmark63)], Williams 2012 [[60](#_bookmark64)]

See text for full explanation of retrieval process. Note that [Chapparo 2012 [11]](#_bookmark15) is cited under opioids as well as anticonvulsants and antidepressants, and [Mujakperuo 2010 [25]](#_bookmark19) is cited under NSAIDs as well as anticonvulsants.

histograms by virtue of lengthening the x-axis in order to capture the very few trials in which active treatment ex- tended beyond a year, we truncated the x-axes in [Figure 1](#_bookmark2) at 15 months.

Downloaded from <http://painmedicine.oxfordjournals.org/>by guest on November 15, 2016

We noted that the distribution of the opioid trials excluded from the 2014 AHRQ report appeared to be an overdispersed Poisson distribution. We therefore fit- ted the plots of active treatment durations vs number of trials using binomial distributions so as to smooth the curves and facilitate visual comparisons with the refer- ence distribution, i.e., the opioid studies retrieved for the 2014 AHRQ opioid evidence report but not selected due to their “inadequate duration.” Comparisons of the 2014 AHRQ opioid trial number-vs-duration distribution with the other modalities commonly employed to treat chronic pain are displayed in [Figure 2](#_bookmark3).

[Table 3](#_bookmark4) provides quantitative comparisons of the data presented visually in [Figures 1](#_bookmark2) and [2](#_bookmark3). The results pre- sented in [Table 3](#_bookmark4) indicate that the durations of the ac- tive interventions in trials of anticonvulsants and behavioral therapies, although numerically shorter than those for opioid trials excluded from the 2014 AHRQ re- view, are not statistically significantly shorter. On the other hand, the duration of NSAID active exposure is

less than half of those in the excluded opioid studies in the 2014 AHRQ review (*P* < 0.001), while the duration of active opioid treatment in the reports included in the

Cochrane opioid review is 2.4 times longer than the opi- oid trials identified but excluded from the 2014 AHRQ review (*P* < 0.001). Thus, the durations of active treat- ment in efficacy or effectiveness trials for chronic pain are shorter, although not always statistically so, for any of the nonopioid modalities (including behavioral treat- ments) than for the opioid trials identified but not utilized

in the 2014 AHRQ evidence review. In turn, the opioid treatment trials retrieved for the latter review are shorter

as a group than those in the aggregated literature on opioids for chronic pain cited in Cochrane systematic reviews of that topic.

Discussion

We conducted an investigation of the nature of the evi- dence for five frequently used interventions for chronic pain recommended in the 2016 CDC guideline [[5](#_bookmark9)] for opioids in chronic pain: pharmacotherapies (anticonvul- sants, antidepressants, NSAIDs, and opioids) and non- drug, behavioral interventions. Our motivation for doing so was curiosity as to why the 2014 AHRQ evidence re- view [[6](#_bookmark10)] and 2016 CDC guideline for the use of opioids in chronic pain [[5](#_bookmark9)] declared that no suitable studies of opioid therapy qualified for inclusion. Earlier systematic reviews [[7](#_bookmark11),[8](#_bookmark12)] in which one or more coauthors of the 2014 AHRQ evidence review [[6](#_bookmark10)] and 2016 CDC guideline [[5](#_bookmark9)] had participated, had identified sufficient studies to conclude, albeit guardedly, that selected pa- tients carefully followed might benefit from such therapy. Because the principal reason for the 2014 and 2016 documents’ exclusion of all retrieved effectiveness and efficacy trials was stated as “inadequate duration,” we focused our analysis upon the durations of active treat- ment in published clinical trials of all six modalities for chronic pain. We did not attempt a reanalysis of the published evidence in favor of or against the use of opi- oids or any other modality for chronic pain. To reach such an overall conclusion was the task of the system- atic reviews themselves, and the fact that none of the reviews of opioids for chronic pain reached an un- equivocal conclusion speaks to the difficulty of synthe- sizing this literature. For example, even the assignment of a binary rating of effective/ineffective to each study was precluded by the heterogeneity of study protocols, participants enrolled, outcomes measured, and differing results at some time points vs others. Had a

Downloaded from <http://painmedicine.oxfordjournals.org/>by guest on November 15, 2016




Figure 1 Durations of active treatment in trials of typical treatments for chronic pain (x-axis) vs numbers of trials

straightforward synthesis of the literature on opioids for chronic pain been possible, it would already have been published; hence the tentative and conditional language of the 2009 [7] and 2010 [8] systematic reviews.

Focusing upon study duration, we used the best avail- able evidence and tabulated the number of studies of each modality vs the duration of exposure to active treatment in all included studies. We included opioid treatment studies that were identified for the 2014 AHRQ and 2016 CDC reports but discarded due to their having durations of active treatment of less than a year. We separately gathered studies of opioid treat- ment that were reported upon in nine Cochrane system- atic reviews [[8](#_bookmark12),[10](#_bookmark15)–[17](#_bookmark29)]. The methods employed to prepare Cochrane reviews are widely accepted as likely to minimize bias in their assessment of treatment effect- iveness and efficacy [[61](#_bookmark66)].


We formally compared the distributions of the lengths of trials using negative binomial regression and found that the lengths of anticonvulsants, behavioral drugs, and antidepressants were about 95%, 87%, and 79%, re- spectively, of those of the AHRQ-selected studies. NSAID trials tend to be shorter, while opioid trails tend to be longer.

The distribution of active treatment duration in the 148 opioid studies retrieved for but not used in the 2014 AHRQ evidence review showed a shorter duration than the 101 opioid studies examined to support nine Cochrane systematic reviews of the same therapy. Nonetheless, in both groups nearly all trials had a dur- ation of 100 days or shorter. The shape of the distribu- tion for the opioid trials retrieved for but not used in the 2014 AHRQ report displays a clustering at the low range and a tapering off toward the high range, i.e., an apparent Poisson distribution [[62](#_bookmark68)]. The qualitative over- dispersed Poisson distribution shape was less evident in the Cochrane opioid trials, which had a greater duration of active treatment than the 2014 AHRQ trials. Similar distribution shapes were evident in the graphical sum- maries of anticonvulsants, antidepressants, NSAIDs, and nondrug behavioral therapies; as a group, these four modalities had equivalent durations, all of which were shorter than the 2014 opioid trials. In summary,

Figure 1. Continued


with each duration (y-axis). The treatments evaluated

were opioids as described in the 2014 AHRQ review (top graph) and the following modalities as described in Cochrane systematic reviews (second from top, pro- ceeding downwards): anticonvulsants, antidepressants, behavioral, NSAIDs, and opioids. To enhance legibility (i.e., to avoid compressing these graphs horizontally), the x-axes were truncated at 15 months; a negligible number of studies exceeded that active treatment duration.




**B**

Duration




**C**

Duration



**D**

Duration




**A**

Duration

Downloaded from <http://painmedicine.oxfordjournals.org/>by guest on November 15, 2016

Figure 2 Pairwise comparisons of curves fitted (i.e., smoothed) to the distributions of active treatment duration vs numbers of trials with that duration, and those of the opioid trials retrieved for 2014 AHRQ opioid evidence review



**E**

Duration

# Table 3 Comparisons of trial duration for varied analgesic interventions for chronic pain

Ratio 95% CI *P*

Intervention

AHRQ opioid Reference – – Anticonvulsant 0.95 (0.81–1.13) 0.565

Antidepressant 0.79 (0.67–0.94) 0.008

Behavioral 0.87 (0.76–1.01) 0.066

NSAIDS 0.49 (0.40–0.60) <0.001

Cochrane opioid 2.36 (2.06–2.72) <0.001

corresponding literatures for anticonvulsant, antidepres- sant, NSAID, and behavioral therapies. Thus we found no evidence for the statement that currently available lit- erature on opioid efficacy and effectiveness are inad- equate to provide clinical guidance. Further, if a one- year minimum threshold for duration of active treatment were required to justify using any of the major typical therapies for chronic pain, then none of these nonopioid therapies could be recommended. Insofar as strength of the recommendation to switch from an opioid to a non- opioid therapy was based upon the durations of active treatment in the corresponding clinical trials, the pub-

lished literature is insufficient to recommend any switch

Data comparison using negative binomial regression reveals that the average durations of exposure to the active interven- tion for anticonvulsants and behavioral modalities do not differ from those in the opioid studies screened for inclusion in, but subsequently excluded from, the 2014 AHRQ review. The duration of active treatment with antidepressants is over 20% shorter than the excluded opioid studies in the 2014 AHRQ review (*P* ¼ 0.008). The duration of NSAID active exposure is less than half of those in the excluded opioid studies in the

2014 AHRQ review (*P* < 0.001), while the duration of active opioid treatment in the reports included in the Cochrane opi-

oid review is 2.4 times longer than the opioid trials identified but in, but subsequently excluded from, the 2014 AHRQ re- view (*P* < 0.001). Except for “AHRQ opioid,” all tabulated data

is from the Cochrane Database of Systematic Reviews (see

[Table 2](#_bookmark1)).

the distribution of active treatment durations in the opi- oid trials retrieved for but not used in the 2014 AHRQ evidence report and 2016 CDC guideline lay between those for the anticonvulsant/antidepressant/NSAID/be- havioral trials and the Cochrane reviews of opioid therapy.

Is it justified to state, as did the 2014 AHRQ evidence report and the 2016 CDC guideline, that there are no trials of opioid therapy whose duration is adequate to in- form clinical guidelines on chronic pain treatment? Based upon the above analysis, the opioid literature retrieved for but not included in the 2014 AHRQ evi- dence report and 2016 CDC guideline has a shorter duration of exposure to active treatment than the stud- ies of opioid therapy included in the nine aggregated Cochrane systematic reviews. Both the AHRQ and Cochrane opioid literatures have longer durations than

from one modality to another.

The similarities between the graphs of numbers of stud- ies vs duration of active treatment in each study suggest that the clinical trial literature concerning therapy for any chronic pain condition represents a balance between its expected target population, ease of recruitment, the anticipated dose and duration of therapy, and its ex- pected effects and adverse effects—all of which may be similar across trials of different types of interventions [[63](#_bookmark70)]. Overall trial duration also reflects, for analgesic tri- als, the feasibility of designing and executing trials in pa- tient cohorts in whom ethical and practical considerations preclude very long exposures to active or placebo treatments [[64](#_bookmark72)]. Academics, regulatory bodies, and commercial sponsors have worked for decades to establish and update guidances in the United States

[[65](#_bookmark73)] and abroad, e.g., Europe [[66](#_bookmark75)], to advise investiga- tors about all aspects of clinical analgesic trials, includ- ing their duration. Presently, international harmonized standards adopted by the United States and Europe recommend that for approval to treat chronic pain, registration trials must show efficacy and acceptable safety in replicate trials of a duration of 12 weeks in a cohort of at least 1,000 patients, with safety data con- tinued for a year in at least 500 patients [[67](#_bookmark78)]. More pro- longed periods of observation were not recommended by those crafting such guidance [[65](#_bookmark73)–[67](#_bookmark78)], given (for ex- ample) their tendency to accrue an enriched population of placebo responders, increasingly greater likelihood of confounding intercurrent conditions or other morbidity, and the tendency for adverse drug reactions to occur early during prolonged exposure [[65](#_bookmark73)–[67](#_bookmark78)]. Therefore, re- gardless of the specific modality studied, analgesic trials of therapies for chronic pain generally adhere to

Downloaded from <http://painmedicine.oxfordjournals.org/>by guest on November 15, 2016

Figure 2. Continued

but excluded because of “inadequate” duration (the reference distribution). In each figure, the AHRQ opioid reference

distribution is shown as a solid line and the comparison treatment (from the Cochrane reviews) as a dashed line. To normalize results and thereby facilitate visual comparisons, the y-axis presents the probability that a clinical trial, or tri- als, having an active duration of the number of days shown on the x-axis contributes to the areas under the entire curve for that intervention. Hence the summed total area under each curve by definition is set at 1. See text for full explanation of statistical analysis. [Figure 2A](#_bookmark3) shows anticonvulsants, 2B shows antidepressants, 2C shows behavioral interventions, 2D shows NSAIDs, and 2E shows the Cochrane opioid reviews.

prevailing regulatory standards and hence rarely exceed 12 weeks of efficacy or effectiveness assessment.

Downloaded from <http://painmedicine.oxfordjournals.org/>by guest on November 15, 2016

Our focus in the present analysis on duration of active treatment reflects our observation that raising the threshold of this inclusion criterion to become greater than a year was responsible for disqualification of an entire literature. That disqualification led to negative conclusions about the efficacy and effectiveness of opi- oid therapy in the AHRQ 2014 evidence review and the 2016 CDC guideline that it informed, as well as other related publications involving one or more authors of these reports and including the same threshold of one year for inclusion of efficacy or effectiveness trials [[68](#_bookmark65)]. These negative conclusions were in contrast to two guardedly positive earlier systematic reviews by the same methodologist, who led the 2009 American Pain Society/American Academy of Pain Medicine guidelines

1. and contributed to a 2010 Cochrane review [[8](#_bookmark12)] of the same topic. Of course, duration of active treatment is only one of many dimensions of evidence-based medicine that must be considered when evaluating and synthesizing the published literature to inform medical practice [[69](#_bookmark67)], and many approaches have been applied to rate the strength of scientific evidence [[70](#_bookmark69)].

Conclusion

To categorize analgesic trials as of “inadequate dur- ation” if their observation period is a year or less is a major departure from existing standards for the duration of published treatment trials for chronic pain, the vast majority of which are 12 weeks or less. The published literature on major drug and nondrug treatments for chronic pain reveals similar profiles across modalities for numbers of studies vs duration of active treatment.

The risks of substance misuse and abuse posed by pre- scriptions of opioids at high doses for long durations— leading to more prolonged periods of opportunity for their diversion and diffusion into the community at large—have appropriately led to numerous efforts to curtail this public health problem. However, basing therapeutic decision-making upon durations of pub- lished clinical efficacy or effectiveness trials does not support choosing any drug or nondrug therapy over an- other. In fact, the opening words of the first recommen- dation of the CDC guideline [[5](#_bookmark9)] (“Nonpharmacologic therapy and nonopioid pharmacologic therapy are pre- ferred for chronic pain”) and the rationale presented dir- ectly below it make no mention of the overwhelmingly strong evidence for significant morbidity and mortality risk from the most likely nonopioid alternatives to opioid therapy for chronic pain: NSAIDs, coxibs, and acet- aminophen [[71](#_bookmark71)–[73](#_bookmark74)]. The morbidity and mortality likely to result from an increased population-wide consumption as a consequence of following this recommendation are difficult to estimate [[74](#_bookmark76)] but likely to be of the same magnitude as from opioids. Safety concerns about these nonopioid alternatives are sufficiently compelling as to have prompted the US FDA to issue its latest of

many NSAID safety warnings in a 2015 “Drug Safety Communication” [[75](#_bookmark77)]. In the future, as more population- based information becomes available to fill existing re- search gaps [[76](#_bookmark79)], clarifying the selection and mainten- ance of patients who may benefit from opioid therapy or other drug or nondrug interventions to control chronic pain must be a high priority.

Acknowledgments

We thank Laura Pavlech DVM MSLS of the Hirsh Health Sciences Library, Tufts University School of Medicine, for assistance with literature retrieval.

Supplementary Data

Supplementary Data can be found online at [http://](http://painmedicine.oxfordjournals.org/) [painmedicine.oxfordjournals.or](http://painmedicine.oxfordjournals.org/)g.

References

* 1. Homer. The Odyssey. 1st ed. New York: Farrar, Straus and Giroux; 1998.
  2. Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: Controversies, current status, and future directions. Exp Clin Psychopharmacol 2008;16(5):405–16.
  3. Volkow ND, McLellan AT. Opioid abuse in chronic pain–misconceptions and mitigation strategies. N Engl J Med 2016;374(13):1253–63.
  4. Carr DB. “Pain is a public health problem”—what does that mean and why should we care? Pain Med 2016;17(4):626–7.
  5. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep 2016;65(1):1–49.
  6. Chou R, Deyo R, Devine B, et al. The effectiveness and risks of long-term opioid treatment of chronic pain. Evidence report/technology assessment No.

218. AHRQ publication No. 14-E005-EF. Rockville, MD: Agency for Healthcare Research and Quality; September 2014. [www.effectivehealthcare.ahrq.gov/](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm) [reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm) (accessed June 2016).

* 1. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guide- lines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113–30.
  2. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010;1:CD006605.
  3. Cochrane Database of Systematic Reviews. Available at: [http://www.cochranelibrary.com/](http://www.cochranelibrary.com/cochrane-database-of-systematic-reviews/index.html) [cochrane-database-of-systematic-reviews/index.html](http://www.cochranelibrary.com/cochrane-database-of-systematic-reviews/index.html) (accessed June 2016).

Downloaded from <http://painmedicine.oxfordjournals.org/>by guest on November 15, 2016

* 1. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev 2012;7:CD008943.
  2. Chaparro LE, Furlan AD, Deshpande A, et al. Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev 2013;8:CD004959.
  3. Gaskell H, Moore RA, Derry S, Stannard C. Oxycodone for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014;6: CD010692.
  4. Haroutounian S, McNicol ED, Lipman AG. Methadone for chronic non-cancer pain in adults. Cochrane Database Syst Rev 2012;11:CD008025. [23152251]
  5. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev 2013;8:CD006146.
  6. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev 2013;10: CD003447.
  7. Santos J, Alarca~o J, Fareleira F, Vaz-Carneiro A, Costa J. Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 2015;5: CD009923.
  8. Wrzosek A, Woron J, Dobrogowski J, Jakowicka- Wordliczek J, Wordliczek J. Topical clonidine for neuropathic pain. Cochrane Database Syst Rev 2015;8:CD010967.
  9. Aboumarzouk OM, Nelson RL. Pregabalin for chronic prostatitis. Cochrane Database Syst Rev 2012;8:CD009063.
  10. Gurusamy KS, Lusuku C, Davidson BR. Pregabalin for decreasing pancreatic pain in chronic pancrea- titis. Cochrane Database Syst Rev 2016;2: CD011522.
  11. Gill D, Derry S, Wiffen PJ, Moore RA. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011;10:CD009183.
  12. Hearn L, Derry S, Moore RA. Lacosamide for neuro- pathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2012;2:CD009318.
  13. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009;3:CD007076.
  14. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibro- myalgia in adults. Cochrane Database Syst Rev 2014;4:CD007938.
  15. Moore RA, Wiffen PJ, Derry S, Lunn MP. Zonisamide for neuropathic pain in adults. Cochrane Database Syst Rev 2015;1:CD011241.
  16. Mujakperuo HR, Watson M, Morrison R, Macfarlane TV. Pharmacological interventions for pain in pa- tients with temporomandibular disorders. Cochrane Database Syst Rev 2010;10:CD00471.
  17. U€ c¸eyler N, Sommer C, Walitt B, Ha€user W. Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev 2013;10:CD010782.
  18. Wiffen PJ, Derry S, Moore RA. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2013;12: CD006044.
  19. Wiffen PJ, Derry S, Lunn MP, Moore RA. Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2013;8: CD008314.
  20. Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014;4:CD005451.
  21. Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for pain in fibromyalgia in adults. Cochrane Database Syst Rev 2015;10:CD008244.
  22. Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for neuropathic pain in adults. Cochrane Database Syst Rev 2015;7:CD011789.
  23. Derry S, Wiffen PJ, Aldington D, Moore RA. Nortriptyline for neuropathic pain in adults. Cochrane Database Syst Rev 2015;1:CD011209.
  24. Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev 2015;8: CD011091.
  25. Ha€user W, Urru'tia G, Tort S, U€ c¸eyler N, Walitt B. Serotonin and noradrenaline reuptake inhibitors (snris) for fibromyalgia syndrome. Cochrane Database Syst Rev 2013;1:CD010292.
  26. Hearn L, Derry S, Phillips T, Moore RA, Wiffen PJ. Imipramine for neuropathic pain in adults. Cochrane Database Syst Rev 2014;5:CD010769.

Downloaded from <http://painmedicine.oxfordjournals.org/>by guest on November 15, 2016

* 1. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibro- myalgia. Cochrane Database Syst Rev 2014;1: CD007115.
  2. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev 2015;7:CD008242.
  3. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007;4: CD005454.
  4. Tort S, Urru'tia G, Nishishinya MB, Walitt B. Monoamine oxidase inhibitors (maois) for fibromyal- gia syndrome. Cochrane Database Syst Rev 2012;4

:CD009807.

* 1. Urquhart DM, Hoving JL, Assendelft WW, Roland M, van Tulder MW. Antidepressants for non-specific low back pain. Cochrane Database Syst Rev 2008;1

:CD001703.

* 1. Walitt B, Urru'tia G, Nishishinya MB, Cantrell SE,

Ha€user W. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. Cochrane Database Syst Rev 2015;6:CD011735.

* 1. Garner SE, Fidan D, Frankish RR, Maxwell L. Rofecoxib for osteoarthritis. Cochrane Database Syst Rev 2005;1:CD005115.
  2. Moore RA, Chi C-C, Wiffen PJ, Derry S, Rice AS. Oral nonsteroidal anti-inflammatory drugs for neuro- pathic pain. Cochrane Database Syst Rev 2015;10: CD010902.
  3. Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev 2008;1:CD000396.
  4. Derry S, Moore RA. Topical capsaicin (low concen- tration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2012;9:CD010111.
  5. Derry S, Matthews PRL, Wiffen PJ, Moore RA. Salicylate-containing rubefacients for acute and chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 2014;11:CD007403.
  6. Anie KA, Green J. Psychological therapies for sickle cell disease and pain. Cochrane Database Syst Rev 2015;5:CD001916.
  7. Bernardy K, Klose P, Busch AJ, Choy EHS, Ha€user

W. Cognitive behavioural therapies for fibromyalgia. Cochrane Database Syst Rev 2013;9:CD009796.

* 1. Boldt I, Eriks-Hoogland I, Brinkhof MWG, et al. Non- pharmacological interventions for chronic pain in people with spinal cord injury. Cochrane Database Syst Rev 2014;11:CD009177.
  2. Eccleston C, Palermo TM, Williams ACdC, et al. Psychological therapies for the management of chronic and recurrent pain in children and adoles- cents. Cochrane Database Syst Rev 2014;5: CD003968.
  3. Eccleston C, Fisher E, Craig L, et al. Psychological therapies (internet-delivered) for the management of chronic pain in adults. Cochrane Database Syst Rev 2014;2:CD010152.
  4. Fisher E, Law E, Palermo TM, Eccleston C. Psychological therapies (remotely delivered) for the management of chronic and recurrent pain in chil- dren and adolescents. Cochrane Database Syst Rev 2015;3:CD011118.
  5. Henschke N, Ostelo RWJG, van Tulder MW, et al. Behavioural treatment for chronic low-back pain. Cochrane Database Syst Rev 2010;7:CD002014.
  6. Kamper SJ, Apeldoorn AT, Chiarotto A, et al. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain. Cochrane Database Syst Rev 2014;9:CD000963.
  7. Karjalainen KA, Malmivaara A, van Tulder MW, et al. Multidisciplinary rehabilitation for fibromyalgia and musculoskeletal pain in working age adults. Cochrane Database Syst Rev 1999;3:CD001984.
  8. Karjalainen KA, Malmivaara A, van Tulder MW, et al. Multidisciplinary biopsychosocial rehabilitation for neck and shoulder pain among working age adults. Cochrane Database Syst Rev 2003;2:CD002194.
  9. Monticone M, Cedraschi C, Ambrosini E, et al. Cognitive-behavioural treatment for subacute and chronic neck pain. Cochrane Database Syst Rev 2015;5:CD010664.
  10. Price JR, Mitchell E, Tidy E, Hunot V. Cognitive be- haviour therapy for chronic fatigue syndrome in adults. Cochrane Database Syst Rev 2008;3: CD001027.
  11. Theadom A, Cropley M, Smith HE, Feigin VL, McPherson K. Mind and body therapy for fibromyal- gia. Cochrane Database Syst Rev 2015;4: CD001980.
  12. Williams ACdC, Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev 2012;11:CD007407.

Downloaded from <http://painmedicine.oxfordjournals.org/>by guest on November 15, 2016

* 1. Cochrane Handbook of Systematic Reviews of Interventions 2011. 2011. Available at: [www.](http://www/) cochrane–handbook.org (accessed June 2016).
  2. Stata online manual. Available at: [http://www.stata.](http://www.stata.com/support/faqs/statistics/overdispersion-and-excess-zeros/) [com/support/faqs/statistics/overdispersion-and-ex](http://www.stata.com/support/faqs/statistics/overdispersion-and-excess-zeros/) [cess-zeros/](http://www.stata.com/support/faqs/statistics/overdispersion-and-excess-zeros/) (accessed July 5, 2016).
  3. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommenda- tions. Pain 2012;153(6):1148–58.
  4. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommenda- tions. Pain 2010;149(2):177–93.
  5. U.S. Department of Health and Human Services, Food Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry anal- gesic indications: Developing drug and biological products. Draft guidance. 2014. Available at: [http://](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM384691.pdf) [www.fda.gov/downloads/Drugs/GuidanceCompliance](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM384691.pdf) [RegulatoryInformation/Guidances/UCM384691.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM384691.pdf) (accessed June 2016).
  6. Committee for Medicinal Products for Human Use, European Medicines Agency. Guideline on the clin- ical development of medicinal products intended for the treatment of pain. 2nd draft. 2015. Available at: [http://www.ema.europa.eu/docs/en\_GB/document\_](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/12/WC500199242.pdf) [library/Scientific\_guideline/2015/12/WC500199242.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/12/WC500199242.pdf) (accessed June 2016).
  7. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. The extent of population exposure to assess clinical safety for drugs intended for long- term treatment of non-life-threatening conditions E1. 1994. Available at: [http://www.ich.org/filead](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E1/Step4/E1_Guideline.pdf) [min/Public\_Web\_Site/ICH\_Products/Guidelines/](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E1/Step4/E1_Guideline.pdf) [Efficacy/E1/Step4/E1\_Guideline.pdf](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E1/Step4/E1_Guideline.pdf) (accessed June 2016).
  8. Chou R, Turner JA, Devine EB, et al. The effective- ness and risks of long-term opioid therapy for chronic pain: A systematic review for a National Institutes of Health Pathways to Prevention work- shop. Ann Intern Med 2015;162:276–86.
  9. Wittink HM, Carr DB, eds. Pain Management: Evidence, Outcomes, and Quality of Life. New York: Elsevier; 2008.
  10. West S, King V, Carey TS, et al. Systems to Rate the Strength of Scientific Evidence. Evidence report/ technology assessment No.47. AHRQ publication No. 02-E016. Rockville, MD: Agency for Healthcare Research and Quality; 2002.
  11. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: An update for clinicians: A scientific statement from the American Heart Association. Circulation 2007;115:1634–42.
  12. Solomon DH, Raassen JA, Glynn RJ, Levin R, Schneeweiss S. The comparative safety of anal- gesics in older adults with arthritis. Arch Intern Med 2010;170:1968–76.
  13. Scarpignato C, Lanas A, Blandizzi C, et al. Safe pre- scribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis—An expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med 2015;13:55.
  14. Simon LS. Non-steroidal anti-inflammatory drugs and their benefits and harms: The challenge of inter- preting meta-analyses and observational data sets when balanced data are not analyzed and reported. Arthritis Res Ther 2015; 17(1):130.
  15. US Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warning that non- aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015. Available at: [http://www.fda.gov/Drugs/DrugSafety/](http://www.fda.gov/Drugs/DrugSafety/ucm451800.htm76) [ucm451800.htm76](http://www.fda.gov/Drugs/DrugSafety/ucm451800.htm76) (accessed June 2016).
  16. The National Institutes of Health. The Interagency Pain Research Coordinating Committee. [http://iprcc.](http://iprcc.nih.gov/National_Pain_Strategy/NPS_Main.htm) [nih.gov/National\_Pain\_Strategy/NPS\_Main.htm](http://iprcc.nih.gov/National_Pain_Strategy/NPS_Main.htm) (ac- cessed March 2016).